Empirical Therapy of Community-Acquired Pneumonia: Advancing Evidence or Just More Doubt?

Pneumonia remains a significant cause of morbidity and mortality, whether community acquired or hospital acquired. Although many microbial pathogens may cause pneumonia, the most commonly encountered are pneumococcus; atypical organisms, such as Mycoplasma pneumoniae or Legionella; and at times Stap...

Full description

Saved in:
Bibliographic Details
Published in:JAMA : the journal of the American Medical Association 2015-07, Vol.314 (4), p.396-397
Main Authors: Mandell, Lionel A, Waterer, Grant W
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - therapeutic use
Antibiotics
beta-Lactams - therapeutic use
Clinical trials
Drug therapy
Humans
Legionnaires' Disease - drug therapy
Macrolides - therapeutic use
Pathogens
Pneumonia
Pneumonia, Bacterial - drug therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pneumonia remains a significant cause of morbidity and mortality, whether community acquired or hospital acquired. Although many microbial pathogens may cause pneumonia, the most commonly encountered are pneumococcus; atypical organisms, such as Mycoplasma pneumoniae or Legionella; and at times Staphylococcus aureus and certain gram-negative rods. As diagnostic tests have increased in availability and sophistication, identifying multiple pathogens in the same patient is increasingly common. Here, Mandell and Waterer highlight Garin et al's study examining the noninferiority of a β-lactam alone compared with a β-lactam and macrolide combination in moderately severe community-acquired pneumonia.
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.2015.3858